Skip to main content
Terug
Watch Compare

Zentalis Pharmaceuticals, Inc.

Datakwaliteit: 100%
ZNTL
Nasdaq Manufacturing Chemicals
€ 4,47
▲ € 1,71 (61,96%)
Marktkapitalisatie: 317,05 M
Prijs
€ 4,47
Marktkapitalisatie
317,05 M
Dagbereik
€ 2,86 — € 4,47
52-Weeksbereik
€ 1,06 — € 4,47
Volume
11.003.944
Openen € 3,02
50D / 200D Gem.
€ 2,52
77,08% above
50D / 200D Gem.
€ 1,82
145,11% above

Quick Summary

Belangrijkste Punten

Negative free cash flow of -125,25 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-51,98%
Onder sectorgemiddelde (-51,02%)
ROIC-40,05%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio7,76
Interest CoverageN/A

Waardering

PE (TTM)
-2,31
Onder sectorgemiddelde (-1,98)
P/B Ratio1,25
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E -2,3 -2,0
P/B 1,3 5,1
ROE % -52,0 -51,0
Net Margin % — -150,2
Rev Growth 5Y % — 9,3
D/E — 0,3

ETFs Holding This Stock

FSCC logo FSCC Federated Hermes MDT Small Cap Core ETF
0,07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -137,06 M
ROE -51,98% ROA -40,37%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -125,25 M
ROIC -40,05% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7,76
Interest Coverage N/A Asset Turnover 0,00
Working Capital 251,13 M Tangible Book Value 252,87 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,31 Forward P/E N/A
P/B Ratio 1,25 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -39,50%
Market Cap 317,05 M Enterprise Value 277,98 M
Per Share
EPS (Diluted TTM) -1,91 Revenue / Share 0,00
FCF / Share -1,77 OCF / Share -1,77
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 91,38%
SBC-Adj. FCF -153,21 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 67,43 M — — —
Net Income -137,06 M -165,84 M -292,19 M -236,81 M -158,73 M
EPS (Diluted) -1,91 -2,33 -4,47 -4,48 0,00
Gross Profit — — — — —
Operating Income -152,81 M -191,19 M -299,51 M -227,29 M -216,54 M
EBITDA — — — — —
R&D Expenses 107,30 M 167,77 M 189,59 M 172,73 M 175,60 M
SG&A Expenses — — — — —
D&A 739.000,0 1,29 M 1,39 M 1,43 M 544.000,0
Interest Expense — — — — —
Income Tax 442.000,0 177.000,0 -601.000,0 -469.000,0 -297.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 288,97 M 430,34 M 551,69 M 539,31 M 454,51 M
Total Liabilities 72,76 M 93,15 M 114,30 M 105,29 M 90,03 M
Shareholders' Equity 216,20 M 337,19 M 437,28 M 434,02 M 364,48 M
Total Debt — — — — —
Cash & Equivalents 36,00 M 33,90 M 28,04 M 43,07 M 59,71 M
Current Assets 253,19 M 386,07 M 496,72 M 451,93 M 350,77 M
Current Liabilities 36,56 M 52,73 M 69,37 M 56,65 M 43,94 M